DE1767285C3 - Verfahren zur Herstellung eines stabilen, hochwirksamen AHF-Konzentrates und Mittel zur Behandlung der Hämophilie - Google Patents
Verfahren zur Herstellung eines stabilen, hochwirksamen AHF-Konzentrates und Mittel zur Behandlung der HämophilieInfo
- Publication number
- DE1767285C3 DE1767285C3 DE1767285A DE1767285A DE1767285C3 DE 1767285 C3 DE1767285 C3 DE 1767285C3 DE 1767285 A DE1767285 A DE 1767285A DE 1767285 A DE1767285 A DE 1767285A DE 1767285 C3 DE1767285 C3 DE 1767285C3
- Authority
- DE
- Germany
- Prior art keywords
- ahf
- concentrate
- precipitate
- polyethylene glycol
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000012141 concentrate Substances 0.000 title claims description 33
- 238000000034 method Methods 0.000 title claims description 27
- 208000031220 Hemophilia Diseases 0.000 title claims description 9
- 208000009292 Hemophilia A Diseases 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 36
- 239000002244 precipitate Substances 0.000 claims description 29
- 229920001223 polyethylene glycol Polymers 0.000 claims description 21
- 239000004471 Glycine Substances 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 18
- 238000001556 precipitation Methods 0.000 claims description 16
- 239000012461 cellulose resin Substances 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 7
- 238000005194 fractionation Methods 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 210000002381 plasma Anatomy 0.000 description 31
- 239000000243 solution Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000798165 Homo sapiens Trichohyalin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- GGNALUCSASGNCK-UHFFFAOYSA-N carbon dioxide;propan-2-ol Chemical compound O=C=O.CC(C)O GGNALUCSASGNCK-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 102000047998 human TCHH Human genes 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FYKDNWHPKQOZOT-UHFFFAOYSA-M sodium;dihydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OP(O)([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FYKDNWHPKQOZOT-UHFFFAOYSA-M 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63483967A | 1967-05-01 | 1967-05-01 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE1767285A1 DE1767285A1 (de) | 1971-08-19 |
| DE1767285B2 DE1767285B2 (de) | 1980-12-04 |
| DE1767285C3 true DE1767285C3 (de) | 1981-08-20 |
Family
ID=24545372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1767285A Expired DE1767285C3 (de) | 1967-05-01 | 1968-04-22 | Verfahren zur Herstellung eines stabilen, hochwirksamen AHF-Konzentrates und Mittel zur Behandlung der Hämophilie |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS594402B1 (enrdf_load_stackoverflow) |
| BE (1) | BE713764A (enrdf_load_stackoverflow) |
| DE (1) | DE1767285C3 (enrdf_load_stackoverflow) |
| DK (1) | DK119626B (enrdf_load_stackoverflow) |
| ES (1) | ES353435A1 (enrdf_load_stackoverflow) |
| FR (1) | FR1589414A (enrdf_load_stackoverflow) |
| GB (1) | GB1178958A (enrdf_load_stackoverflow) |
| IT (1) | IT1048951B (enrdf_load_stackoverflow) |
| NL (1) | NL162838C (enrdf_load_stackoverflow) |
| SE (1) | SE375008B (enrdf_load_stackoverflow) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (enrdf_load_stackoverflow) * | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| US3803115A (en) | 1972-05-17 | 1974-04-09 | Baxter Laboratories Inc | Stabilization of ahf using heparin |
| DE2550011C2 (de) * | 1975-11-07 | 1982-11-25 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines antihämophilen Mittels |
| DK144731C (da) | 1976-07-30 | 1982-10-18 | Nordisk Insulinlab | Fremgangsmaade til isolering af proteinhormoner stammende fra humant hypofysevaev |
| US4278594A (en) * | 1979-06-19 | 1981-07-14 | David Amrani | Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma |
| FR2460305A2 (fr) * | 1979-06-29 | 1981-01-23 | Merieux Inst | Procede de preparation d'un concentre de facteur viii |
| DE3163003D1 (en) * | 1980-01-18 | 1984-05-17 | Canadian Red Cross | Method of obtaining factor viii |
| DE3318521A1 (de) * | 1983-05-20 | 1984-11-22 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats |
| CA1293941C (en) * | 1985-11-08 | 1992-01-07 | Maria Erlinda Co-Sarno | Method for preparing antihemophilic factor (ahf) by cold precipitation and for improving solubility of recovered ahf product |
| ES2053684T3 (es) | 1988-11-05 | 1994-08-01 | Octapharma Ag | Procedimiento para preparar un factor antihemofilico, altamente puro, no infeccioso, mediante cromatografia. |
| DE3926034C3 (de) * | 1989-08-07 | 1996-11-21 | Behringwerke Ag | Verfahren zur Herstellung eines stabilen Faktors VIII |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL286954A (enrdf_load_stackoverflow) * | 1962-01-03 |
-
1968
- 1968-04-17 BE BE713764D patent/BE713764A/xx not_active IP Right Cessation
- 1968-04-22 DK DK178768AA patent/DK119626B/da not_active IP Right Cessation
- 1968-04-22 DE DE1767285A patent/DE1767285C3/de not_active Expired
- 1968-04-23 FR FR1589414D patent/FR1589414A/fr not_active Expired
- 1968-04-25 SE SE6805574A patent/SE375008B/xx unknown
- 1968-04-29 IT IT36633/68A patent/IT1048951B/it active
- 1968-05-01 NL NL6806162.A patent/NL162838C/xx not_active IP Right Cessation
- 1968-05-01 GB GB20604/68A patent/GB1178958A/en not_active Expired
- 1968-05-02 ES ES353435A patent/ES353435A1/es not_active Expired
-
1973
- 1973-10-11 JP JP48114294A patent/JPS594402B1/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS594402B1 (enrdf_load_stackoverflow) | 1984-01-30 |
| NL6806162A (enrdf_load_stackoverflow) | 1968-11-04 |
| DE1767285A1 (de) | 1971-08-19 |
| DE1767285B2 (de) | 1980-12-04 |
| DK119626B (da) | 1971-02-01 |
| IT1048951B (it) | 1980-12-20 |
| SE375008B (enrdf_load_stackoverflow) | 1975-04-07 |
| ES353435A1 (es) | 1969-09-16 |
| NL162838B (nl) | 1980-02-15 |
| NL162838C (nl) | 1980-07-15 |
| BE713764A (enrdf_load_stackoverflow) | 1968-09-16 |
| GB1178958A (en) | 1970-01-28 |
| FR1589414A (enrdf_load_stackoverflow) | 1970-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2324717C3 (de) | Verfahren zur Herstellung eines stabilen AHF-Konzentrates (Faktor VIII) | |
| DE2459291C3 (de) | Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen | |
| DE69333928T2 (de) | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes | |
| DE2029455C3 (de) | Verfahren zur Herstellung eines neuen Prothrombinkomplexes | |
| DE2854381A1 (de) | Verfahren zur gewinnung des antihaemophilen faktors viii aus blut, blutplasma oder blutplasma-fraktionen | |
| DE3150318C2 (de) | "Verfahren zur Herstellung eines Polysaccharidderivats des Fibrinolysins" | |
| DE1767285C3 (de) | Verfahren zur Herstellung eines stabilen, hochwirksamen AHF-Konzentrates und Mittel zur Behandlung der Hämophilie | |
| Bertke et al. | Effect of Centruroides sculpturatus venom upon rat tissue: a histopathologic study | |
| DE2715832B2 (de) | Verfahren zur Gewinnung von gereinigtem antihämophilem Globulin A (Faktor VIII) | |
| DE3686390T2 (de) | Verfahren zur herstellung vom antihaemophilfaktor (ahf) durch kaeltefaellung und zur verbesserung der loeslichkeit des hergestellten ahf-produktes. | |
| CH641044A5 (de) | Prostacyclin und prostacyclin-derivate enthaltende pharmazeutische zubereitung und verfahren zu ihrer herstellung. | |
| DE1076888B (de) | Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke | |
| DE3019895C2 (enrdf_load_stackoverflow) | ||
| EP0127025A2 (de) | Verfahren zur Herstellung eines Antihämophiliefaktor-Konzentrats | |
| DE2515666A1 (de) | Neues proteinprodukt, dessen herstellung und verwendung | |
| DE2428955A1 (de) | Verfahren zur extraktion von bestandteilen mit in vivo antikoagulierender wirkung aus schlangengiften und daraus erhaltene produkte | |
| DE1932527C3 (de) | Verfahren zur Herstellung eines blutstillenden Praeparates | |
| DE2409650C3 (de) | Verwendung wäßriger Lösung von menschlichem Serum-Haptoglobin bei der Bekämpfung von hämolytischen Nierenstörungen | |
| DE1818054C2 (de) | Verfahren zur Gewinnung von cytobiotischen Globulinen | |
| DE2262520C3 (de) | Verfahren zur Herstellung eines lyophilisierten, lagerfähigen Konzentrats aus menschlichem Plasma | |
| DE960579C (de) | Verfahren zur Herstellung eines in der Hitze sterilisierbaren Adrenocorticotropin-Praeparates | |
| DE2246969C2 (de) | Urokinase-Heparinat und dieses enthaltende Arzneimittel | |
| DE4115910C2 (enrdf_load_stackoverflow) | ||
| AT214572B (de) | Verfahren zur Gewinnung von Properdin | |
| AT336182B (de) | Verfahren zur herstellung eines prothrombinkomplexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8310 | Action for declaration of annulment | ||
| 8313 | Request for invalidation rejected/withdrawn |